Patient (PT) understanding of venous thromboembolism (VTE) risks associated with lenalidomide (Len) and thalidomide (Thal), previous clots, and current prophylaxis.

e16512 Background: PTs takingLen and Thal alone or in combination with high dose dexamethasone are at risk for deep venous thrombosis (DVT) and pulmonary embolism (PE). PT and provider awareness of VTE and optimal means of prevention is relatively unknown. This ongoing cross-sectional survey assessed the following objectives: 1) PT understanding of VTE risk associated with Len and Thal, 2) previous history of VTE among these PTs, and 3) current prophylaxis. Methods: A novel collaboration was developed between the specialty service demonstration outpatient pharmacy site (Walgreens Pharmacy) at Northwestern, and the Research on Adverse Drug Events and Reports (RADAR) team. A survey was developed and administered to PTs who filled a prescription for Len or Thal between July 2009 and December 2009. This pharmacy is the primary on-site location for outpatient prescriptions associated with the NCI-designated Robert H. Lurie Comprehensive Cancer Center at Northwestern. Results: A total of 23 PTs met eligibility ...